Biotransformation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in peripheral human lung microsomes. 2003

Graeme B J Smith, and John R Bend, and Leanne L Bedard, and Ken R Reid, and Dimitri Petsikas, and Thomas E Massey
Department of Pharmacology and Toxicology, Queen's University Kingston, Ontario, Canada.

The contributions of different enzymes to 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) biotransformation were assessed in human lung microsomes prepared from peripheral lung specimens obtained from seven subjects. Metabolite formation was expressed as a percentage of total recovered radioactivity from [5-3H]NNK and its metabolites per milligram of protein per minute. 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol was the major metabolite formed in the presence of an NADPH-generating system, with production ranging from 0.5186 to 1.268%/mg of protein/min, and total NNK bioactivation (represented by the sum of the four alpha-carbon hydroxylation endpoint metabolites) ranged from 0.002100 to 0.005685% alpha-hydroxylation/mg of protein/min. Overall, production of bioactivation metabolites was greater than that of detoxication (i.e., N-oxidation) products. Based on total bioactivation, subjects could be classified as high or low NNK bioactivators. In the presence of an NADPH-generating system, microsomal formation of the endpoint metabolite 1-(3-pyridyl)-1-butanone-4-carboxylic acid (keto acid) was consistently higher than that of all other alpha-carbon hydroxylation endpoint metabolites. Contributions of cytochrome p450 (p450) enzymes to NNK oxidation were demonstrated by NADPH dependence, inhibition by carbon monoxide, and inhibition by the nonselective p450 inhibitors proadifen hydrochloride (SKF-525A) and 1-aminobenzotriazole (ABT), particularly in lung microsomes from high bioactivators. At 5.0 mM, ABT inhibited total NNK bioactivation by 54 to 100%, demonstrating the importance of ABT-sensitive enzyme(s) in human pulmonary NNK bioactivation. Contributions of CYP2A6 and/or CYP2A13, as well as CYP2B6, to NNK bioactivation were also suggested by selective chemical and antibody inhibition in lung microsomes from some subjects. It is likely that multiple p450 enzymes contribute to human pulmonary microsomal NNK bioactivation, and that these contributions vary between individuals.

UI MeSH Term Description Entries
D008168 Lung Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood. Lungs
D008297 Male Males
D008861 Microsomes Artifactual vesicles formed from the endoplasmic reticulum when cells are disrupted. They are isolated by differential centrifugation and are composed of three structural features: rough vesicles, smooth vesicles, and ribosomes. Numerous enzyme activities are associated with the microsomal fraction. (Glick, Glossary of Biochemistry and Molecular Biology, 1990; from Rieger et al., Glossary of Genetics: Classical and Molecular, 5th ed) Microsome
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009602 Nitrosamines A class of compounds that contain a -NH2 and a -NO radical. Many members of this group have carcinogenic and mutagenic properties. Nitrosamine
D002273 Carcinogens Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. Carcinogen,Oncogen,Oncogens,Tumor Initiator,Tumor Initiators,Tumor Promoter,Tumor Promoters,Initiator, Tumor,Initiators, Tumor,Promoter, Tumor,Promoters, Tumor
D003577 Cytochrome P-450 Enzyme System A superfamily of hundreds of closely related HEMEPROTEINS found throughout the phylogenetic spectrum, from animals, plants, fungi, to bacteria. They include numerous complex monooxygenases (MIXED FUNCTION OXYGENASES). In animals, these P-450 enzymes serve two major functions: (1) biosynthesis of steroids, fatty acids, and bile acids; (2) metabolism of endogenous and a wide variety of exogenous substrates, such as toxins and drugs (BIOTRANSFORMATION). They are classified, according to their sequence similarities rather than functions, into CYP gene families (>40% homology) and subfamilies (>59% homology). For example, enzymes from the CYP1, CYP2, and CYP3 gene families are responsible for most drug metabolism. Cytochrome P-450,Cytochrome P-450 Enzyme,Cytochrome P-450-Dependent Monooxygenase,P-450 Enzyme,P450 Enzyme,CYP450 Family,CYP450 Superfamily,Cytochrome P-450 Enzymes,Cytochrome P-450 Families,Cytochrome P-450 Monooxygenase,Cytochrome P-450 Oxygenase,Cytochrome P-450 Superfamily,Cytochrome P450,Cytochrome P450 Superfamily,Cytochrome p450 Families,P-450 Enzymes,P450 Enzymes,Cytochrome P 450,Cytochrome P 450 Dependent Monooxygenase,Cytochrome P 450 Enzyme,Cytochrome P 450 Enzyme System,Cytochrome P 450 Enzymes,Cytochrome P 450 Families,Cytochrome P 450 Monooxygenase,Cytochrome P 450 Oxygenase,Cytochrome P 450 Superfamily,Enzyme, Cytochrome P-450,Enzyme, P-450,Enzyme, P450,Enzymes, Cytochrome P-450,Enzymes, P-450,Enzymes, P450,Monooxygenase, Cytochrome P-450,Monooxygenase, Cytochrome P-450-Dependent,P 450 Enzyme,P 450 Enzymes,P-450 Enzyme, Cytochrome,P-450 Enzymes, Cytochrome,Superfamily, CYP450,Superfamily, Cytochrome P-450,Superfamily, Cytochrome P450
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Graeme B J Smith, and John R Bend, and Leanne L Bedard, and Ken R Reid, and Dimitri Petsikas, and Thomas E Massey
November 1995, Biochemical pharmacology,
Graeme B J Smith, and John R Bend, and Leanne L Bedard, and Ken R Reid, and Dimitri Petsikas, and Thomas E Massey
September 1985, IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans,
Graeme B J Smith, and John R Bend, and Leanne L Bedard, and Ken R Reid, and Dimitri Petsikas, and Thomas E Massey
September 1999, Carcinogenesis,
Graeme B J Smith, and John R Bend, and Leanne L Bedard, and Ken R Reid, and Dimitri Petsikas, and Thomas E Massey
June 2000, Carcinogenesis,
Graeme B J Smith, and John R Bend, and Leanne L Bedard, and Ken R Reid, and Dimitri Petsikas, and Thomas E Massey
December 1995, Cancer research,
Graeme B J Smith, and John R Bend, and Leanne L Bedard, and Ken R Reid, and Dimitri Petsikas, and Thomas E Massey
November 2007, Drug metabolism and disposition: the biological fate of chemicals,
Graeme B J Smith, and John R Bend, and Leanne L Bedard, and Ken R Reid, and Dimitri Petsikas, and Thomas E Massey
March 1998, Naunyn-Schmiedeberg's archives of pharmacology,
Graeme B J Smith, and John R Bend, and Leanne L Bedard, and Ken R Reid, and Dimitri Petsikas, and Thomas E Massey
July 1998, Cancer letters,
Graeme B J Smith, and John R Bend, and Leanne L Bedard, and Ken R Reid, and Dimitri Petsikas, and Thomas E Massey
February 2000, Cancer letters,
Graeme B J Smith, and John R Bend, and Leanne L Bedard, and Ken R Reid, and Dimitri Petsikas, and Thomas E Massey
June 2013, Biochemical and biophysical research communications,
Copied contents to your clipboard!